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Effect of concomitant HIV infection on adverse drug reactions by first 
line antitubercular drugs - a case series analysis
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Abstract   
 
The pattern and severity of adverse drug reactions (ADRs) due to first-line anti-tubercular drugs in solely tubercular 
and TB-HIV co-infected patients could be different due to drug-disease and drug-drug interactions in TB-HIV co-
infected patients. Nevertheless, the studies regarding this aspect are very meager. Hence a retrospective appraisal of 
individual case safety reports (ICSR) due to first-line antitubercular drugs spontaneously submitted to the ADR 
monitoring center was done for solely tubercular and TB-HIV coinfected patients. Out of eight ICSRs, four had 
concomitant HIV infection, and two of them were on antiretroviral (ARV) drugs. Co-infected patients showed rare and 
severe ADRs like optic neuritis, acute renal failure, and drug-induced liver injury (DILI). In contrast, four non-HIV co-
infected tubercular patients suffered from comparatively less severe cutaneous reactions and vertigo. A high negative 
(-0.774) correlation coefficient between HIV co-infection and recovery status found that HIV co-infected patients had 
low chances of fully recovering. In conclusion, HIV co-infection and ARV drugs can affect the pattern, severity, and 
recovery status of adverse drug reactions due to first-line antitubercular drugs.   
Keywords: Adverse Drug Reactions (ADR), TB-HIV Co-infection, First Line Antitubercular Drugs (FLD), 
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Background  
Tuberculosis (TB) and human immunodeficiency virus (HIV) 
are highly infectious diseases commonly encountered in the 
Asian-Pacific region. According to the WHO global 
tuberculosis report 2014, HIV prevalence was 6.3 % in new TB 
cases in this region and was on an increasing trend [1]. As 
multiple drugs are used for a longer duration in both of them, so 
the possibility of drug-drug and drug-disease interactions are 
high in TB-HIV coinfected patients. Isoniazid, rifampicin, 
pyrazinamide, and ethambutol, abbreviated as HRZE, are used 
as first line antitubercular drugs (FLD) in tuberculosis treatment 
as per guidelines. For HIV, the national AIDS control 
organization approves multiple regimens, but in practice, 
tenofovir, lamivudine, and efavirenz, abbreviated as TLEf or 
zidovudine, lamivudine, efavirenz (ZdLEf), are preferred.  
Common adverse drug reactions (ADRs) encountered due to 
FLD are nausea, vomiting, jaundice, arthralgia, pruritus, 
abdominal pain, paresthesia, numbness, mental disturbances, 
rash, fever, lethargy, and diarrhea. 
In contrast, shock, renal failure, loss of diabetes control, and 
optic neuritis are rare but serious adverse effects. Antiretroviral 
drugs mainly show hematologic and skin reactions as adverse 
effects [2,3]. The purpose of this case series analysis is to 
compare and analyze the pattern and severity of adverse drug 
reactions due to anti-tubercular drugs in solely tubercular and 
TB-HIV co-infected patients. For this, we analyzed the 
individual case safety reports (ICSR) submitted to ADR 
Monitoring Center (AMC) at Sawai Man Singh (SMS) 
Hospital, Jaipur from Chest and TB department in 2019.  
     SMS Hospital AMC was set up in 2011 as a part of the 
Pharmacovigilance Programme of India (PvPI). PvPI was 
initiated on 14th July 2010 under the aegis of the Ministry of 
Health and family welfare with headquarter in Ghaziabad to 
safeguard public health by validating the safety of medicinal 
products [4].  As of 2020, there are 311 AMCs in India which 
collect spontaneously submitted 4000-5000 individual case 
safety reports (ICSRs) every month. These collected ICSRs are 
analyzed and subjected to provisional causality assessment 
before directing them towards the national coordinating centre 
(NCC) in Ghaziabad for further proceedings and finally 
submitted to the Uppsala monitoring centre, Sweden through 
VigiFlow. SMS Hospital AMC contributes about 20-30 ICSRs 
every month to the NCC-PvPI. Most of the hospital ADRs are 
reported from cancer, HIV, skin, medicine, and TB 
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departments. While assessing the ICSRs from the TB 
department in the present study, demographic factors, 
associated HIV disease and its treatment, suspected 
antitubercular drug in combination, and the lag time between 
antitubercular treatment (ATT) and reporting ADR, the severity 
of ADR together with recovery status were noted. WHO-UMC 
scale and Hartwig scale were used for casualty and severity 
assessment, respectively [5, 6].  Individual case vignettes are as 
follows. 
 
Case 1-  
A male patient 40 years of age presented with complaints of 
progressively decreased vision six months after starting ATT 
therapy for extrapulmonary TB. At the time of ADR, he was 
receiving Isoniazid (H), rifampicin (R), ethambutol (E) in doses 
5mg/kg, 10mg/kg, 15mg/kg, respectively. He was a naïve case 
of HIV diagnosed simultaneously with TB for which he was 
started the TLEf regimen by oral route two weeks after initiating 
ATT. Doses used were 300, 300, 600 mg for tenofovir, 
lamivudine, and efavirenz, respectively. The patient did not 
recover from vision loss even after stopping the ethambutol. 
 
Case 2-  
A male patient of 55 years was a known HIV case for 12 years 
on Zd LEf (600, 300, and 600 mg respectively every day). He 
had a previous history of pulmonary TB as an opportunistic 
infection eight years back, for which he had received ATT for 
nine months and was declared cured. Now he again developed 
TB on November 18 and started ATT. He presented with a 
history of feeling a continuous decrease in the vision on January 
19. Ethambutol was stopped immediately and replaced by 
pyrazinamide. However, he did not improve even after two 
months. In both the above cases, rechallenge was not done with 
ethambutol, and patients did not improve either after stopping 
the suspected drug. 
 
Case 3-  
A 43 years old naïve TB-HIV co-infected male patient on ATT 
presented with complaints of severe diarrhea, vomiting, and 
decreased urine. His serum creatinine levels, and blood urea 
nitrogen levels were increased to 544µmol/l and 49 mmol/l, 
respectively, within two weeks of starting ATT in contrast to 
124µmol/l and 10 mmol/l before initiation of ATT. Liver 
function tests were normal. Temporal association and effect of 
ethambutol withdrawal to stop clinical condition worsening 
identified ethambutol as the suspected drug. However, biopsy 
reports were not available, and the reintroduction of ethambutol 
was not attempted. The patient did not recover fully.    
 
Case 4-  
A female patient of 63 years of age was on a TLEf regimen for 
three months. Then she developed tuberculosis, for which she 
was started a quadrupled ATT regimen. She was hospitalized 
with clinically evident jaundice after two months of initiating 
therapy. Total bilirubin was 53µmol/l, and ALT/AST levels 
were 358/92 units per liter (U/L), respectively. It fulfilled the 
criteria of drug-induced liver injury (DILI), which states either 
liver enzymes more than five times of upper limit of normal or 
more than three times of upper limit of normal with symptoms 
of hepatitis or jaundice (bilirubin>51 µmol/l) [7]. All ATT 
drugs were stopped, and after 12 days of stopping, ATT 
baseline value of bilirubin and ALT/AST returned to 27µmol/l 
and 55/32 per liter, respectively. Isoniazid (H) and rifampicin 
(R) were resumed without any further side effects, but the 
pyrazinamide (Z), which was the main suspected drug, does not 
reintroduced. 
 
Cases 5-8-  
Amongst the solely tubercular patients, one male smoker patient 
developed severe nausea and vertigo with pyrazinamide's first 
dose. Symptoms subsided with a reduction of dose from 1250 to 
750 mg, and again increase in dose after two days was well 
tolerated. No lab tests were done. Rest three tubercular patients 
presented with equally distributed, itchy, macular rashes all 
over the chest and abdomen with or without skin excoriation 
after seven to ten days of initiating ATT. Isoniazid (H) was the 
suspected drug, and on discontinuing it, they all recovered. 
Demographic characteristics reported ADRs, and other findings 
are given in table 1.  
 
Statistical analysis 
The mean age of the tubercular patients with ADR was 44 
years. For calculating the correlation coefficient between HIV 
and recovery status, firstly, number “0” was assigned to those 
who did not recover, and number "1" was assigned to those who 
recovered. Similarly, for the presence of HIV, number “1” was 
assigned and “0” for the absence of HIV in the study patients, 
as shown below: 
 
Then the following formula for 
Correlation Coefficient was applied in 
Minitab 14 software, Pennsylvania 
(PA) 
 





 √∑ 𝒙𝟐−(?̅?𝟐)√∑ 𝒚𝟐−(?̅?𝟐)
    
Where 𝑥 ̅and ?̅? are the mean values for the series x(recovery) 
and y (HIV). The correlation coefficient value came out to be -
0.774, which shows a negative and high correlation between 
HIV and recovery. So, it was concluded that as the patient is 
HIV positive, there is a very low chance to recover fully. 
 
Discussion  
Ethambutol is a bacteriostatic drug that acts by inhibiting 
arabinosyltransferase required for mycobacterial cell wall 
synthesis. It is also a metal chelator that chelates iron and 
copper-containing complexes richly present in mitochondria. As 
a result, oxidative phosphorylation has interfered with the 
increased production of reactive oxygen species. Since the 
papillomacular bundle is rich in mitochondria, more damage to 
the optic pathway [8].  
     Hence, optic neuritis is a rare but significant adverse effect 
of ethambutol, which requires the drug's withdrawal. Human 
immunodeficiency virus produces cytokine and TNF-mediated 
secondary inflammatory changes in optic nerves predisposing 
them to develop optic nerve toxicity. After the priming by HIV 
infection, when ethambutol in concomitant TB co-infection is 
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Table 1 Demographic characteristics reported ADRs, and other findings (n=8) 
0 months*=simultaneously diagnosed, ADRs= Adverse Drug Reaction, S. No= case serial number 
 
It is usually reversible and dose-dependent, but it was 
irreversible in our study and occurred at an optimum dose of 
15mg/kg/day as approved in guidelines. To add more, Mustak 
et al. [11] have found that Nucleoside analog reverse 
transcriptase inhibitors (NRTIs) used in HIV therapy may be a 
risk factor for developing toxic optic neuropathy from 
ethambutol therapy by virtue of their additional potential 
mitochondrial toxic effects. They called it a multiple hit effect 
[11]. A number of second-line injectable drugs such as 
aminoglycosides used in multidrug-resistant tuberculosis cases 
are nephrotoxic, but very few renal toxicity cases by FLD have 
been reported. Hughes et al. [12] have very recently explained 
that HIV-infected renal epithelial cells proliferate after 
acquiring the virus from macrophages, and it may contribute to 
precipitate renal failure in susceptible patients on ATT [12]. It 
seems that HIV infection rather than ARV contributes to renal 
disease as the patient in our study was also naïve to 
antiretroviral drugs, as in another similar study by Narayana et 
al. [13]. Ramappa et al. [14] found that concomitant HIV 
infection increases the risk of anti-TB drug-induced 
hepatotoxicity significantly (4 times), and the use of highly 
active anti-retroviral therapy further increases hepatotoxicity. 
The reason could be due to interactions together with immune 
reconstitution. They emphasized that a sequential regimen with 
or without pyrazinamide would be suitable for individuals who 
have a higher baseline prediction of hepatotoxicity as defined 
by their phenotype of malnutrition, low albumin, alcoholics, 
and HIV-positive individuals [14]. We also stopped 
pyrazinamide, and the patient recovered in a few days. 
     Amongst the non-HIV co-infected tubercular patients, 
reactions were moderately severe, with three of them suffering 
from skin reactions all over the thorax and abdomen, and one 
had excessive nausea and vertigo. All were possible on the 
WHO-UMC scale except one certain skin reaction due to 
isoniazid who developed rash again on reintroduction, and 
isoniazid was withdrawn. All FLD and SLD in tuberculosis can 
cause cutaneous reactions, the commonest being isoniazid in 
FLD [7,15]. Second-line anti- Koch drugs like aminoglycosides 
used in multidrug-resistant and extremely drug-resistant TB are 
notorious for causing ototoxicity with vertigo as the most 
common vestibular symptoms followed by tinnitus and hearing 
loss [16].  However, the non –HIV patient in our study suffered  
 
 
from severe nausea and vertigo with FLD, which abated with 
the decrease in pyrazinamide dose. 
 
Limitations of the study  
The study focused on one time ADR collected by the 
pharmacovigilance centre. Secondly, being an institution based 




The study largely shows that HIV co-infection and ARV can 
affect the pattern, severity, and recovery from toxicity due to 
antitubercular drugs. TB-HIV co-infection is a recent evolving 
infectious epidemic in the Asia- Pacific region. Hence research 
focused on identifying possible drug-disease and drug-drug 
interactions, and drug modulations should be promoted, and 




TB: Tuberculosis; ADR: Adverse Drug Reaction; HIV: Human 
Immunodeficiency Virus;  PV: Pharmacovigilance; ICSR: Individual 
Case Safety Reports; ARV: Antiretroviral; FLD: First Line 
antitubercular Drugs; WHO: World Health Organization; AIDS: Acute 
Immune Deficiency Syndrome; H: isoniazid; R: rifampicin; Z: 
pyrazinamide; E: ethambutol; Zd: zidovudine;  L: lamivudine; Ef: 
efavirenz; ATT: Antitubercular Treatment; AST: Aspartate 
Transaminase; ALT: Alanine Transaminase; DILI: Drug-Induced Liver 
Injury; TNF: Tumor Necrosis Factor; NRTI: Nucleoside Reverse 
Transcriptase Inhibitors; SLD: Second Line Antitubercular Drugs; 




The author (s) would like to acknowledge all the HCW who reported 
adverse drug reactions to the PV centre.  
 
Funding  
The authors received no financial support for their research, authorship, 
and/or publication of this article. 
 
Availability of data and materials  
Data will be available by emailing alkabansal04@gmail.com 




ADR reported Suspected 
antitubercular drug  
ADR Onset 







1 40 M 49 Yes 0 months* Optic neuritis Ethambutol (E) 185 days Possible Yes No  
2 55 M 48 Yes 12 years  Optic neuritis Ethambutol(E) 115 days Possible Yes  No  
3 43 M 49 Yes 0 months* Renal failure Ethambutol(E) 14 days Possible Yes No 
4 63 F 43 Yes 6 months DILI Pyrazinamide (Z)  58 days Possible Yes  Yes  
5 21 F 28 No - Skin reaction Isoniazid(H) 7 days Possible No Yes  
6 52 M 40 No - Skin reaction Isoniazid (H) 10 days Certain No  Yes  
7 26 F 28 No  Skin reaction Isoniazid (H) 7 days Possible  No  Yes  
8 52 M 43 No -  Severe 
nausea, vertigo 
Pyrazinamide (Z) O days Possible No Yes  
                                            Bansal A., Sharma L., Journal of Ideas in Health (2020);3(3):222-225                                                               225  
 
Authors’ contributions  
AB is the principal investigator in this manuscript. She observed the 
findings, conceived the concept, designed, and developed the study, 
including its writing, editing, and approved the manuscript in its present 
form. LS participated in data procurement, its analysis, revision, and 
approved the manuscript. Authors have read and approved the final 
manuscript. 
 
Ethics approval and consent to participate  
The study was conducted in duly compliance with the established 
international publishing and reporting recommendations by the 
EQUATOR network for enhancing quality and transparency in health 
research. We followed the principles of the declaration of Helsinki. The 
approval of the Institutional Ethics committee, SMS Hospital, Jaipur, 
was obtained via letter No. 4123/ MC/EC/2018 dated 9/10/18. 
 
Consent for publication  
Not applicable 
 
Competing interest   
The author declares that he has no competing interests. 
 
Open Access  
This article is distributed under the terms of the Creative Commons 
Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate if 
changes were made. The Creative Commons Public Domain Dedication 
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to 
the data made available in this article, unless otherwise stated. 
 
Author details  
1Department of Pharmacology, Sawai Man Singh (SMS) Medical 
College, Jaipur, India.  2Department of Pharmacology and Co-
Ordinator, Pharmacovigilance centre, Sawai Man Singh (SMS) Medical 
College, Jaipur, Rajasthan, India. 
 
Article Info  
Received: 12 September 2020  
Accepted: 09 October 2020    
Published: 26 October 2020 
 
References  
1. World Health Organization. Global tuberculosis report 2014. 
Geneva: WHO; 2014. Accessed from 
https://apps.who.int/iris/handle/10665/137094 [Accessed on 5 
September 2020) 
2. Tripathi KD. Essentials of medical pharmacology. JP Medical 
Ltd; 2013 Sep 30. 
3. Katzung BG. Basic and clinical pharmacology. Mc Graw Hill; 
2012. 
4. Amale PN, Deshpande SA, Nakhate YD, Arsod NA (2018) 
Pharmacovigilance Process in India: An overview. J 
Pharmacovigil 6: 259. https://doi.org/10.4172/2329-6887.1000259 
5. The use of the WHO–UMC system for standardised case causality 
assessment. Accessed from: http://www.WHO-
UMC.org/graphics/4409.pdf [Accessed on 5 September 2020) 
6. Padmavathi S, Manimekalai K, Ambujam S. Causality, severity 
and preventability assessment of adverse cutaneous drug reaction: 
a prospective observational study in a tertiary care hospital. 
Journal of clinical and diagnostic research: JCDR. 2013 
Dec;7(12):2765.  https://doi.org/10.7860/JCDR/2013/7430.3753 
7. Prasad R, Singh A, Gupta N. Adverse drug reactions in 
tuberculosis and management. Indian Journal of Tuberculosis. 
2019;66(4):520-32. https://doi.org/10.1016/j.ijtb.2019.11.005  
8. Warner JE, Ries KM. Optic neuropathy in a patient with AIDS. 
Journal of neuro-ophthalmology. 2001;21(2):92-4. https://doi.org 
/10.1097/00041327-200106000-00006 
9.  Sadun AA, Pepose JS, Madigan MC, Laycock KA, Tenhula WN, 
Freeman WR. AIDS-related optic neuropathy: a histological, 
virological and ultrastructural study. Graefe's archive for clinical 
and experimental ophthalmology. 1995;233(7):387-98. 
https://doi.org/10.1007/BF00180941 
10. Lin XH, Kashima Y, Khan M, Heller KB, Gu XZ, Sadun AA. 
Short Communication: An immunohistochemical study of TNF-a 
in optic nerves from AIDS patients. Current eye research. 
1997;16(10):1064-8. https://doi.org/10.1076/ceyr.16.10.1064.9017 
11. Mustak H, Rogers G, Cook C. Ethambutol induced toxic optic 
neuropathy in HIV positive patients. International Journal of 
Ophthalmology.2013;6(4):542. 
https://doi.org/10.3980/j.issn.2222-3959.2013.04.25 
12. Hughes K, Akturk G, Gnjatic S, Chen B, Klotman M, Blasi M. 
Proliferation of HIV-infected renal epithelial cells following virus 
acquisition from infected macrophages. AIDS. 2020;34(11):1581-
1591. https://doi.org/10.1097/QAD.0000000000002589 
13. Prasad N, Patel MR. Infection-induced kidney diseases. Frontiers 
in Medicine. 2018 Nov 28;5: 327.  
https://doi.org/10.3389/fmed.2018.00327 
14. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis 
drugs: mechanisms and management. Journal of clinical and 
experimental hepatology. 2013;3(1):37-49. https:// doi.org/ 
10.1016/j.jceh.2012.12.001. 
15. Hoosen K, Mosam A, Dlova NC, Grayson W. An update on 
adverse cutaneous drug reactions in HIV/AIDS. 
Dermatopathology.2019;6(2):111-25. 
https://doi.org/10.1159/000496389 
16. Ramma L, Ibekwe TS. Cochleo-vestibular clinical findings among 
drug resistant Tuberculosis Patients on therapy-a pilot study. 
International archives of medicine. 2012;5(1):3. 
https://doi.org/10.1186/1755-7682-5-3. 
